DE60043070D1 - Proteine-abgabe durch polare epithelzellen schichte - Google Patents

Proteine-abgabe durch polare epithelzellen schichte

Info

Publication number
DE60043070D1
DE60043070D1 DE60043070T DE60043070T DE60043070D1 DE 60043070 D1 DE60043070 D1 DE 60043070D1 DE 60043070 T DE60043070 T DE 60043070T DE 60043070 T DE60043070 T DE 60043070T DE 60043070 D1 DE60043070 D1 DE 60043070D1
Authority
DE
Germany
Prior art keywords
bioactive
epithelial cells
protein delivery
moiety
polar epithelial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60043070T
Other languages
German (de)
English (en)
Inventor
David J Fitzgerald
Randall J Mrsny
Miriam Mckee
Ann Daugherty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
US Department of Health and Human Services
Original Assignee
Genentech Inc
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, US Department of Health and Human Services filed Critical Genentech Inc
Application granted granted Critical
Publication of DE60043070D1 publication Critical patent/DE60043070D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60043070T 1999-10-22 2000-10-18 Proteine-abgabe durch polare epithelzellen schichte Expired - Lifetime DE60043070D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16092399P 1999-10-22 1999-10-22
PCT/US2000/029080 WO2001030392A2 (en) 1999-10-22 2000-10-18 Delivery of proteins across polar epithelial cell layers

Publications (1)

Publication Number Publication Date
DE60043070D1 true DE60043070D1 (de) 2009-11-12

Family

ID=22579051

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60043070T Expired - Lifetime DE60043070D1 (de) 1999-10-22 2000-10-18 Proteine-abgabe durch polare epithelzellen schichte

Country Status (8)

Country Link
US (1) US7824695B1 (enExample)
EP (1) EP1242122B1 (enExample)
JP (2) JP2003512441A (enExample)
AT (1) ATE444081T1 (enExample)
AU (1) AU784657B2 (enExample)
CA (1) CA2389302C (enExample)
DE (1) DE60043070D1 (enExample)
WO (1) WO2001030392A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2295971C (en) * 1997-07-11 2011-02-08 THE GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Pseudomonas exotoxin a-like chimeric immunogens
ATE444081T1 (de) 1999-10-22 2009-10-15 Us Gov Health & Human Serv Proteine-abgabe durch polare epithelzellen schichte
EP1804832A4 (en) * 2004-10-04 2008-12-24 Trinity Biosystems Inc METHOD AND COMPOSITIONS FOR THE NADLESS DELIVERY OF MACROMOLECULES
CA2631952A1 (en) 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of antibodies
US20090148401A1 (en) * 2005-12-05 2009-06-11 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
CA2647168A1 (en) * 2006-03-16 2007-09-27 Trinity Biosystems, Inc. Methods for increasing the size of animals using needleless delivery constructs
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
EP4082558B1 (en) 2018-03-08 2023-08-23 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
SG11202104734YA (en) 2018-11-07 2021-06-29 Applied Molecular Transport Inc Cholix-derived carriers for oral delivery of heterologous payload
BR112022002962A2 (pt) 2019-08-16 2022-07-05 Applied Molecular Transport Inc Composições, formulações e produção e purificação de interleucina

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
AU4646393A (en) * 1992-06-23 1994-01-24 Interactive Biologics Associates Pharmaceutical composition containing botulinum b complex
EP0717753B1 (en) * 1993-09-06 1998-12-02 Menarini Ricerche S.p.A. Ribosome inactivating proteins extracted from seeds of saponaria ocymoides and vaccaria pyramidata, their preparation and immunotoxins containing them
CA2190101A1 (en) 1994-05-13 1995-11-23 Donald Leonard Nicholas Cardy Improvements in or relating to peptide delivery
EP0941334B1 (en) * 1996-11-06 2004-06-02 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Protease-activatable pseudomonas exotoxin a-like proproteins
WO1998042876A1 (en) 1997-03-26 1998-10-01 Board Of Regents, The University Of Texas System Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
US20030054012A1 (en) 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
CA2295971C (en) * 1997-07-11 2011-02-08 THE GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Pseudomonas exotoxin a-like chimeric immunogens
US6472140B1 (en) 1997-09-05 2002-10-29 The General Hospital Corporation α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease.
ATE444081T1 (de) 1999-10-22 2009-10-15 Us Gov Health & Human Serv Proteine-abgabe durch polare epithelzellen schichte
AU779473B2 (en) 1999-10-22 2005-01-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Disulfide conjugated cell toxins and methods of making and using them
DK1379550T3 (da) 2000-12-21 2009-07-06 Us Gov Health & Human Serv Et kimært protein omfattende non-toxisk pseudomonas exotoxin A og en type IV pilin sekvenser

Also Published As

Publication number Publication date
JP2012051939A (ja) 2012-03-15
CA2389302A1 (en) 2001-05-03
EP1242122B1 (en) 2009-09-30
ATE444081T1 (de) 2009-10-15
JP2003512441A (ja) 2003-04-02
US7824695B1 (en) 2010-11-02
WO2001030392A2 (en) 2001-05-03
AU1339201A (en) 2001-05-08
CA2389302C (en) 2011-03-15
WO2001030392A3 (en) 2002-07-11
EP1242122A2 (en) 2002-09-25
AU784657B2 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
Maggi The mammalian tachykinin receptors
Niedel et al. Receptor-mediated internalization of fluorescent chemotactic peptide by human neutrophils
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
NO2017028I1 (no) eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
CY1118504T1 (el) Τριμερης πρωτεϊνη συντηξης του συνδετη οχ40 στην περιοχη ανοσοσφαιρινης και τροποι χρησης
PT835266E (pt) Superantigenios modificados / quimericos e seu uso
DK0817847T4 (da) IL-17-receptor
DE60025832D1 (de) Mehrere zytokin-antikörper komplexen
DE68923990D1 (de) Zellen mit ausgestattener Antikörperspezifität.
DE60043070D1 (de) Proteine-abgabe durch polare epithelzellen schichte
OA07388A (fr) Nouveaux conjugués associant, par liaison convalente, une enzyme et un anticorps et associations médicamenteuses utilisant lesdits conjugués.
DK1331944T3 (da) Anvendelse af CD28-specifikke monoklonale antistoffer til stimulering af blodlegemer, der ikke bærer CD28
ATE311464T1 (de) Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungen
ATE297219T1 (de) Antikörper als arzneimittel gegen lymphocytische tumore (ausschliesslich myelome)
PT969873E (pt) Hidrato de carbono glicopeptido antigene multiplo, vacina abrangendo o mesmo e seu uso
AR042968A1 (es) Anticuerpos de virus anti-dengue composiciones metodos y usos
DE69130457D1 (de) Peptidfragmente des env-proteins vom immunschwäche-virus der katze und ihre verwendung in der diagnostik
DK1196196T3 (da) Konjugat til formidling af en celle-, compartment- eller membranspecifik transport af aktivstoffer
WAKSMAN Overview: Biology of the lymphokines
SE9604470D0 (sv) Transmembrane component of tight junction
Pelletier et al. Down modulation of Heymann's nephritis by mercuric chloride
WO2001059073A3 (en) Cytotoxic t lymphocytes activated by dendritic cell hybrids
ES2122921B1 (es) Proteinas recombinantes de fusion del virus reproductivo y respiratorio porcino (prrsv) y su empleo en diagnostico.
WO1992016623A3 (en) Receptors for bombesin-like peptides

Legal Events

Date Code Title Description
8364 No opposition during term of opposition